Alivus Life Sciences Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹650Cr
- +21% YoY
- +1.2% QoQ
- Net profit
- ₹142Cr
- +44.9% YoY
- +3.6% QoQ
- Margin
- 31%
- +5 pp YoY
- +1 pp QoQ
Guidance rank: #71 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
FY’26 volume growth expected in mid-teens, driven by new product launches and opening of new markets. Volume Growth: Mid-teens volume growth expected in FY’26 driven by new product launches and market expansion.
From Alivus Life Sciences Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY’26 volume growth expected in mid-teens, driven by new product launches and opening of new markets.
- Revenue growth projected to be in high single digits due to pricing erosion despite volume growth.
- Incremental volume growth primarily from newer product sites, though base products continue solid volume growth.
- CDMO business expected to grow significantly with 4th project reaching full potential by end FY’25 and 5th project obtaining regulatory approval in second half FY’26.
- Longer-term, growth is backed by a strong pipeline with product launches aligned with patent expiries starting FY’28.
2 more points from Alivus Life Sciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Alivus Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Total planned CAPEX for FY’26 is upwards of Rs. 550 crores (Rs. 550-600 crores range).
- Major CAPEX includes:
- Greenfield expansion in Solapur.
- Brownfield expansions in Ankleshwar and Dahej to be completed this year.
- New R&D center near Mumbai with Rs. 70-80 crores allocated.
- The 2650 KL volume expansion initially planned for FY’27 is now pushed to FY’28 due to brownfield expansions providing sufficient capacity for next 2-3 years.
- Asset turnover may be lower initially during this investment phase but expected to reach around 2x gradually.
- Focus remains on completing brownfield expansions and Solapur Phase 1 (300 KL) by Q4 FY’26.
2 more points from Alivus Life Sciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Alivus Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The CDMO business has a small base with three commercial projects currently driving volume.
- The 4th CDMO project started commercializing in Q3 of the previous year but is on a slow uptake, expected to reach full potential by end of the current year.
- The 5th CDMO project is under regulatory approvals, with an anticipated approval for use as an API source in the second half of FY’26.
- There are ongoing discussions and multiple projects ("irons in the fire") in the CDMO pipeline aimed at bringing more projects by late FY’26 or early FY’27.
2 more points from Alivus Life Sciences Ltd's call on order book
Create a free account to keep reading this call
Alivus Life Sciences Ltd — Quarterly revenue & net profit
Alivus Life Sciences Ltd Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 650 | 537 | +21% | 642 | +1.2% |
| Operating profit (EBITDA) | 198 | 141 | +40.4% | 190 | +4.2% |
| Operating margin | 31% | 26% | +5 pp | 30% | +1 pp |
| Profit before tax | 191 | 130 | +46.9% | 185 | +3.2% |
| Net profit (PAT) | 142 | 98 | +44.9% | 137 | +3.6% |
| EPS (₹) | 11.58 | 7.99 | +44.9% | 11.18 | +3.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹682 Cr, net profit ₹197 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Alivus Life Sciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharmaceuticals (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Alivus Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Alivus Life Sciences Ltd Q4 FY25 results?
FY’26 volume growth expected in mid-teens, driven by new product launches and opening of new markets. Volume Growth: Mid-teens volume growth expected in FY’26 driven by new product launches and market expansion.
What is Alivus Life Sciences Ltd share price analysis?
Alivus Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 26.3 with a market cap of ₹16,341 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alivus Life Sciences Ltd planning capital expenditure?
Total planned CAPEX for FY’26 is upwards of Rs. 550 crores (Rs. 550-600 crores range).
Keep Alivus Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
